American Century Companies Inc Lyell Immunopharma, Inc. Transaction History

American Century Companies Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$1.3 - $3.01 $55,577 - $128,683	42,752 Added 18.06%	279,425 $405,000
Q1 2024 May 14, 2024	BUY	$1.71 - $3.07 $155,999 - $280,069	91,228 Added 62.72%	236,673 $527,000
Q4 2023 Feb 13, 2024	BUY	$1.39 - $2.35 $202,168 - $341,795	145,445 New	145,445 $282,000
Q3 2023 Nov 13, 2023	BUY	$1.45 - $3.35 $59,207 - $136,790	40,833 Added 50.97%	120,951 $177,000
Q2 2023 Aug 14, 2023	BUY	$1.89 - $3.86 $61,840 - $126,299	32,720 Added 69.03%	80,118 $254,000
Q1 2023 May 11, 2023	BUY	$1.97 - $3.58 $15,300 - $27,805	7,767 Added 19.6%	47,398 $111,000
Q4 2022 Feb 13, 2023	BUY	$2.78 - $8.09 $37,516 - $109,174	13,495 Added 51.63%	39,631 $137,000
Q3 2022 Nov 14, 2022	BUY	$5.54 - $8.27 $144,793 - $216,144	26,136 New	26,136 $192,000

122

142M

18.1K

200

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $273M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

Stay updated on American Century Companies Inc with notifications on news.